Emraclidine is a positive allosteric modulator (PAM) designed to selectively target the M4 muscarinic receptor subtype. M4 muscarinic receptor subtypes have been shown to influence the levels of acetylcholine and dopamine, key neurotransmitters in the brain that are known to be dysregulated in diseases like schizophrenia. Emraclidine is currently being evaluated for the treatment of schizophrenia.
